Concert Pharma falls 13% after third quarter results

  • Concert Pharma (NASDAQ:CNCE) stock fell sharply on Monday despite the biopharma reporting a loss lighter than expected for third quarter.
  • The Lexington-based drug developer focused on the treatment of autoimmune diseases reported a loss of $0.58 per share, notching a earnings surprise from consensus

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.